2023 World Conference on Lung Cancer (Posters)-EP07.01. Can the Use of New Haemostatic Agent Improve Short Term Outcomes of Surgically Treated Non-small Cell Lung Cancer Patients?

EP07.01. Can the Use of New Haemostatic Agent Improve Short Term Outcomes of Surgically Treated Non-small Cell Lung Cancer Patients? - PDF(Slides)

Back to course

Pdf Summary

The study aimed to evaluate the impact of a haemostatic agent called Microporous Polysaccharide Hemospheres (ARISTA) on the short-term outcomes of patients undergoing surgery for non-small cell lung cancer. The study used a retrospective analysis of data from two European centers between October 2020 and December 2022.<br /><br />The cohort included a total of 482 patients, with 226 cases where ARISTA was used intraoperatively. The results showed that the use of ARISTA was associated with a significant reduction in surgical time, shorter hospitalization, shorter chest tube duration, and decreased fluid drainage compared to the control group. Linear regression analysis confirmed the superior results of ARISTA compared to the control group.<br /><br />There were no cases of bleeding, blood transfusion, 30-day mortality, or redo surgery observed in the ARISTA group. The study concluded that ARISTA is a safe and effective haemostatic device and that its use has a positive effect on short-term postoperative outcomes in patients with early-stage lung cancer.<br /><br />Overall, the study suggests that the use of ARISTA can improve outcomes in surgically treated non-small cell lung cancer patients by reducing blood loss, decreasing fluid drainage, and shortening hospital stay.

Asset Subtitle

Sara Ricciardi

Meta Tag

Speaker Sara Ricciardi

Topic Early-Stage NSCLC: Best Practice

Keywords

haemostatic agent

Microporous Polysaccharide Hemospheres

ARISTA

short-term outcomes

surgery

non-small cell lung cancer

retrospective analysis

linear regression analysis

blood loss reduction

hospital stay reduction